Encompass Wealth Advisors LLC Sells 3,010 Shares of Amgen Inc. $AMGN

Encompass Wealth Advisors LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 50.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,997 shares of the medical research company’s stock after selling 3,010 shares during the period. Encompass Wealth Advisors LLC’s holdings in Amgen were worth $981,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Board of the Pension Protection Fund bought a new position in shares of Amgen during the 4th quarter valued at $26,000. Olistico Wealth LLC bought a new position in shares of Amgen during the 4th quarter valued at $33,000. Cloud Capital Management LLC bought a new position in shares of Amgen during the 3rd quarter valued at $34,000. Saranac Partners Ltd bought a new position in shares of Amgen during the 3rd quarter valued at $37,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Amgen during the 4th quarter valued at $37,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on AMGN. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Morgan Stanley raised their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Daiwa Securities Group upped their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $355.16.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 data for a subcutaneous/on‑body TEPEZZA injector showed strong efficacy and safety vs IV, potentially enabling at‑home dosing and broader use for Thyroid Eye Disease — this could expand TEPEZZA’s addressable market and improve convenience-driven uptake. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Royal Bank of Canada lifted its price target to $370, a bullish signal that supports upside versus prior analyst levels and may underpin buying interest. Royal Bank Of Canada Increases Amgen Price Target to $370
• Positive Sentiment: Investors continue to focus on Amgen’s push into GLP‑1/obesity (MariTide — move to a once‑quarterly injectable was highlighted), which positions the company in a high‑growth segment and complements its existing biologics portfolio. We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play.
• Neutral Sentiment: Analysts/market pieces note recent share gains and market outperformance, reflecting broader healthcare strength and momentum rather than company‑specific catalysts alone. Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: Guggenheim and Cantor Fitzgerald have maintained/reaffirmed neutral ratings ($351 and $350 targets respectively), signaling limited near‑term upside from their perspectives and keeping sentiment mixed. Guggenheim Adjusts Amgen Price Target Cantor Fitzgerald Reaffirms Neutral
• Negative Sentiment: Morgan Stanley kept a Hold and a $309 target, highlighting limited near‑term upside and providing a counterweight to bullish notes — this could pressure sentiment if investors focus on valuation gaps. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
• Negative Sentiment: Competitive pressure from Eli Lilly (and other GLP‑1 leaders) and debates over IMID positioning remain a risk to market share and pricing power in obesity/immunology categories. Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs

Amgen Price Performance

AMGN stock opened at $355.60 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a market cap of $191.91 billion, a P/E ratio of 24.99, a PEG ratio of 3.47 and a beta of 0.47. The firm has a 50-day moving average of $363.69 and a 200 day moving average of $334.30. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the firm earned $5.31 earnings per share. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.